Roche : new up leg in sight ?
Nicolas Suiffet June 19, 2020 5:33 PM
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS).
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer, but the other co-primary endpoint of rPFS in the overall study population was not met.
From a chartist's point of view, the short term consolidation started in May could be over as prices have landed on a key support at 320CHF and are posting a rebound. The breakout confirmation of the 20DMA is a bullish event. The daily Relative Strength Index (RSI, 14) is pushing above its declining trend line. The general up trend remains in place.
Readers may want to consider the potential for long positions above the horizontal support at 320CHF with 351CHF and 358CHF as targets. Alternatively, a break below 320CHF would invalidate the bullish trend and would call for a down move towards 298CHF.
Source: GAIN Capital, TradingView
From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.